drugset / Trial / NCT02859324
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.
Timeline
- Start
- 2016-09-20
- Primary completion
- 2020-03-27
- Completion
- 2020-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avadomide | Other / unclassified | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |